Induction, STabilization, Adherence, and Retention Trial (ISTART) - A Randomized, Non-inferiority, Multicenter Study to Assess Early Treatment Efficacy of OX219 Versus SUBOXONE Film and to Explore Switching Between Treatments
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Buprenorphine/naloxone (Primary) ; Buprenorphine
- Indications Opioid-related disorders
- Focus Registrational; Therapeutic Use
- Acronyms ISTART
- Sponsors Orexo
- 26 Sep 2015 Primary endpoint (The proportion of randomized subjects retained in treatment. at Day 15) has been met according to the results published in the Clinical Therapeutics.
- 26 Sep 2015 Primary endpoint (The proportion of randomized subjects retained in treatment. at Day 3) has been met according to the results published in the Clinical Therapeutics.
- 24 Sep 2015 Results published in the Clinical Therapeutics.